Regeneron Pharmaceuticals Competitors and Similar CompaniesClear all
Regeneron Pharmaceuticals's competitors and similar companies include Intersect ENT, Catalent, Bristol Myers Squibb, Idorsia, Amgen, Sanofi and Biogen.
 Regeneron Pharmaceuticals Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines. |  Intersect ENT Intersect ENT (also known as Medtronic Ear, Nose & Throat) is an ear, nose, and throat medical technology company. |  Catalent Catalent is a company that develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products. |  Bristol Myers Squibb Bristol-Myers Squibb (BMS) is a company engaged in the discovery, development, licensing, manufacturing, marketing, and distribution of biopharmaceutical products. |  Idorsia Idorsia, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs. |  Amgen Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics. |  Sanofi Sanofi is a healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions. |  Biogen Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases. | |
Founding Date | Founding Date 1988 | Founding Date 2003 | Founding Date 2007 | Founding Date 1887 | Founding Date 2017 | Founding Date 1980 | Founding Date 1994 | Founding Date 1978 |
Type | Type Public | Type Subsidiary | Type Subsidiary | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||||
Locations | Locations Tarrytown, US HQ Mississauga, CA Courbevoie, FR München, DE Bengaluru, IN Dublin, IE Limerick, IE see more | Locations Menlo Park, US HQ | Locations Bridgewater, US HQ Buenos Aires, AR Bruxelles, BE Charleroi, BE Charleroi, BE Charleroi, BE Indaiatuba, BR see more | Locations Princeton, US HQ Mulgrave, AU Pinewood, AU Wien, AT Braine L'alleud, BE Bruxelles, BE São Paulo, BR see more | Locations Allschwil, CH HQ Shanghai, CN Lörrach, DE Chiyoda City, JP | Locations Thousand Oaks, US HQ Hydra, DZ Vicente López, AR Sydney, AU Wien, AT Diegem, BE Santo Amaro, BR see more | Locations Paris, FR HQ Hydra, DZ Buenos Aires, AR Macquarie Park, AU Melbourne, AU Virginia, AU Wien, AT see more | Locations Cambridge, US HQ Vicente López, AR Macquarie Park, AU Wien, AT Machelen, BE São Paul, BR Toronto, CA see more |
Employees | Employees 15,1068% increase | Employees 4337% increase | Employees 12,6955% increase | Employees 34,100 | Employees 8007% increase | Employees 25,200 | Employees 82,878 | Employees 7,605 |
Valuation ($) | Valuation ($) 102.2 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 97.8 b | Valuation ($) N/A | Valuation ($) 170.4 b | Valuation ($) 141.1 b | Valuation ($) 26.7 b |
Financial | ||||||||
Revenue (est.) | Revenue (est.) $14.3b (FY, 2025) | Revenue (est.) $106.7m (FY, 2021) | Revenue (est.) $4.4b (FY, 2024) | Revenue (est.) $48.2b (FY, 2025) | Revenue (est.) CHF220.6m (FY, 2025) | Revenue (est.) $36.8b (FY, 2025) | Revenue (est.) €45.4b (FY, 2025) | Revenue (est.) $9.9b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $30m (FY, 2021) | Cost of goods $3.4b (FY, 2024) | Cost of goods $13.9b (FY, 2025) | Cost of goods CHF20.9m (FY, 2025) | Cost of goods $12b (FY, 2025) | Cost of goods €11.6b (FY, 2025) | Cost of goods $2.4b (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $76.7m (FY, 2021) | Gross profit $953m (FY, 2024) | Gross profit $34.3b (FY, 2025) | Gross profit CHF214.3m (FY, 2025) | Gross profit $24.7b (FY, 2025) | Gross profit €37.6b (FY, 2025) | Gross profit $7.5b (FY, 2025) |
Net income | Net income $4.5b (FY, 2025) | Net income ($159.6m) (FY, 2021) | Net income ($1b) (FY, 2024) | Net income $7.1b (FY, 2025) | Net income (CHF111.7m) (FY, 2025) | Net income $7.7b (FY, 2025) | Net income €8b (FY, 2025) | Net income $1.3b (FY, 2025) |
Operating ⚠ | ||||||||
Countries | Countries N/A | Countries N/A | Countries 80 (FY, 2023) | Countries N/A | Countries N/A | Countries 100 (FY, 2020) | Countries N/A | Countries N/A |
Facilities | Facilities N/A | Facilities 1 (FY, 2016) | Facilities N/A | Facilities N/A | Facilities N/A | Facilities 180 (FY, 2020) | Facilities N/A | Facilities N/A |
Patents (EU) | Patents (EU) 17 (FY, 2020) | Patents (EU) N/A | Patents (EU) N/A | Patents (EU) N/A | Patents (EU) N/A | Patents (EU) 21 (FY, 2020) | Patents (EU) N/A | Patents (EU) N/A |
Patents (US) | Patents (US) 31 (FY, 2020) | Patents (US) 30 (FY, 2016) | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) 31 (FY, 2020) | Patents (US) N/A | Patents (US) N/A |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 20 (FY, 2020) | Phase I Trials Products N/A | Phase I Trials Products 4 (FY, 2024) |
Phase I Trials Products (Oncology) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 20 (FY, 2021) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 9 (FY, 2021) | Phase I Trials Products (Oncology) N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 5 (FY, 2020) | Phase II Trials Products N/A | Phase II Trials Products 6 (FY, 2024) |
Phase II Trials Products (Oncology) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 15 (FY, 2021) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 12 (FY, 2021) | Phase II Trials Products (Oncology) N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 11 (FY, 2020) | Phase III Trials Products N/A | Phase III Trials Products 11 (FY, 2024) |
Products | Products 11 (FY, 2022) | Products 2 (FY, 2016) | Products 8 k (FY, 2023) | Products N/A | Products N/A | Products N/A | Products N/A | Products N/A |
Projects in R&D Pipeline | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline 12 (FY, 2019) | Projects in R&D Pipeline N/A | Projects in R&D Pipeline 91 (FY, 2019) | Projects in R&D Pipeline N/A |
Trademarks | Trademarks 20 (FY, 2022) | Trademarks 29 (FY, 2016) | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks N/A |
Funding | ||||||||
Total funding raised | Total funding raised $ 53.9m | Total funding raised $ 102.9m | Total funding raised $ 650m | Total funding raised $ 15.5m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 310m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Intersect ENT
HQ
Menlo Park, US
Intersect ENT (also known as Medtronic Ear, Nose & Throat) is an ear, nose, and throat medical technology company.
View companyCatalent
HQ
Bridgewater, US
Catalent is a company that develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products.
View companyBristol Myers Squibb
HQ
Princeton, US
Employees
34,100
Bristol-Myers Squibb (BMS) is a company engaged in the discovery, development, licensing, manufacturing, marketing, and distribution of biopharmaceutical products.
View companyIdorsia
HQ
Allschwil, CH
Employees
800↑ 7% increase
Idorsia, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs.
View company